Avalo Therapeutics (NASDAQ:AVTX) Receives “Buy” Rating from HC Wainwright

Avalo Therapeutics (NASDAQ:AVTX)‘s stock had its “buy” rating reissued by equities researchers at HC Wainwright in a report issued on Thursday,Benzinga reports. They currently have a $25.00 price target on the stock. HC Wainwright’s price objective points to a potential upside of 54.42% from the stock’s current price.

A number of other equities analysts also recently issued reports on the company. Weiss Ratings restated a “sell (d-)” rating on shares of Avalo Therapeutics in a research note on Friday, January 9th. Mizuho upgraded Avalo Therapeutics to a “strong-buy” rating in a research note on Thursday, December 18th. Finally, BTIG Research reiterated a “buy” rating and issued a $40.00 target price on shares of Avalo Therapeutics in a research report on Monday, September 29th. One investment analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat.com, Avalo Therapeutics has an average rating of “Moderate Buy” and a consensus price target of $32.71.

Avalo Therapeutics Price Performance

Shares of NASDAQ:AVTX opened at $16.19 on Thursday. Avalo Therapeutics has a 1 year low of $3.39 and a 1 year high of $20.72. The company has a market cap of $299.68 million, a PE ratio of -3.02 and a beta of 0.84. The stock’s 50-day moving average is $17.59 and its 200 day moving average is $12.98.

Avalo Therapeutics (NASDAQ:AVTX) last released its quarterly earnings results on Thursday, November 6th. The company reported ($2.19) earnings per share for the quarter, missing the consensus estimate of ($1.67) by ($0.52). Analysts expect that Avalo Therapeutics will post -19.07 EPS for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the stock. BIT Capital GmbH purchased a new position in Avalo Therapeutics during the 3rd quarter worth approximately $25,000. Geode Capital Management LLC grew its stake in Avalo Therapeutics by 2.5% in the 2nd quarter. Geode Capital Management LLC now owns 110,460 shares of the company’s stock valued at $552,000 after acquiring an additional 2,648 shares during the period. Quadrature Capital Ltd purchased a new stake in shares of Avalo Therapeutics during the second quarter worth about $55,000. Dimensional Fund Advisors LP acquired a new position in shares of Avalo Therapeutics during the third quarter valued at approximately $143,000. Finally, Boothbay Fund Management LLC purchased a new position in Avalo Therapeutics in the 2nd quarter valued at $56,000. Hedge funds and other institutional investors own 87.06% of the company’s stock.

About Avalo Therapeutics

Avalo Therapeutics is a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies for cardiometabolic, fibrotic and inflammatory diseases. The company’s proprietary drug-design platform enables the creation of long-acting prodrugs with optimized pharmacokinetic profiles, aiming to improve efficacy, safety and patient adherence. By leveraging this technology, Avalo seeks to address key drivers of disease progression that remain underserved by existing treatments.

Its lead programs include AVTX-002, a first-in-class prodrug candidate designed to inhibit angiotensinogen for the treatment of hypertension and related cardiovascular disorders, and AVTX-006, an early-stage candidate targeting pathways implicated in fibrosis and metabolic dysfunction.